Cybin Corp. is Canada’s premier mushroom life-sciences company focused on advancing psychedelic and nutraceutical-based products derived from fungi. A recent article discussing the company reads, “In particular, Cybin aims to further build upon and expand its intellectual property (‘IP’) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic … Continue reading “NetworkNewsBreaks – Why Cybin Corp. Is ‘One to Watch’”
Cybin is a leading Canada-based mushroom life sciences company focused on psychedelic medicines and nutraceutical products The company has two operating divisions – Serenity Life Sciences (psychedelic pharmaceutical products) and Natures Journey Inc. (medicinal nutraceutical products) Members of Cybin’s experienced management team have collectively run multiple clinical trials and helped facilitate over $1 billion in … Continue reading “Cybin Corp. is “One to Watch””
Cybin Corp., Canada’s premier mushroom life sciences company focused on advancing psychedelic and nutraceutical-based products derived from fungi, today announced its entry into a feasibility agreement with IntelGenx Corp. (OTCQB: IGXT) (TSX-V:IGX) for the development of an orally-dissolving film for the delivery of pharmaceutical-grade psilocybin, subject to receipt of all necessary regulatory approvals. “We at … Continue reading “NetworkNewsBreaks – Cybin Corp. and IntelGenx Corp. to Collaborate in Development of Fast-Acting Psilocybin Film”
Cybin Corp., a mushroom life sciences company focused on psychedelic medicines and nutraceutical products, on Monday announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly-owned subsidiary of Clarmin. According to the update, completion of the transactions contemplated in the agreement will … Continue reading “NetworkNewsBreaks – Cybin Corp. Announces Reverse Take-Over and Up-To $21M Concurrent Private Placement”
Disseminated on behalf of Cybin Inc., may include paid advertisements. Investment Considerations Cybin Inc. currently has three molecules in development with four sponsored clinical trials planned for 2022 and a preclinical pipeline of 50+ novel assets. The company’s management team is composed of leaders with experience in various aspects of the pharmaceutical and innovative therapeutics … Continue reading “Cybin Inc. (NYSE American: CYBN) (NEO: CYBN)”
Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a human optimization sciences company that is advancing its clinical pipeline through its ongoing TBI/PTSD-focused preclinical studies at the University of Miami’s Miller School of Medicine, today announced that its research partner and lead investigator, Dr. Michael Hoffer, has obtained a sustainable supply of psilocybin under a … Continue reading “NetworkNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) Research Partner Secures Steady Psilocybin Supply for Clinical Studies”
Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a human-optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, offers a timely line of organic, non-GMO and vegan-certified products. In 2019, Johns Hopkins launched a center for psychedelic research … Continue reading “NetworkNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) Aims to Support Mental Health, Develop Improved Treatments Using Psilocybin Mushrooms”
Psyence Biomed (NASDAQ: PBM) has announced that its Chief of Global Impact, Mary-Elizabeth Gifford, was selected as a featured speaker at Psychedelic Science 2025 (“PS2025”) – the world’s largest international gathering focused on psychedelic research, biopharma, medicine, policy, and culture. Hosted by the Multidisciplinary Association for Psychedelic Studies (“MAPS”), the highly anticipated conference is taking … Continue reading “NetworkNewsBreaks – Psyence Biomedical Ltd. (NASDAQ: PBM) to Present at Psychedelic Science 2025”
Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of Republican lawmakers advocating for the therapeutic use of psychedelics to treat PTSD, depression, and suicidality among veterans—a movement recently spotlighted by The Wall Street Journal. After undergoing ibogaine and DMT therapy in Mexico in 2018, Luttrell described the experience as … Continue reading “Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform “
Cannadelic Miami 2025, held at the Miami Airport Convention Center, Miami, FL, from May 23 to 24, 2025. This transformative two-day event empowers attendees to explore the frontiers of emerging therapies, plant-based medicine, and next-gen healing. Based on the inspiring theme “Elevate Your Experience. Transform Your Life,” Cannadelic Miami is a must-attend event for individuals … Continue reading “NECANN Cannadelic Miami 2025 to Ignite Miami’s Wellness Evolution”
